“So as I said I think it's the same story for both of those technologies, where you push growth now but into next year will the full impact of these innovations.”

In context

“r to Sean to talk about AFib and then Aurora. Sean Salmon: Yeah, thanks, Geoff. And Matt the trajectory is obviously going to be upward for both the EV-ICD as well as the CAS business in total. As you launch these new technologies, there are some training that you have to do to make sure that the physicians are comfortable with how to use the products and that's of course something we are very deliberate about to make sure that there is a good patient outcome and good acceptance of the technology. And that's something we do pretty frequently at our business. So we're really, really good at it. And the feedback has been excellent. The procedure efficiency on PulseSelect has been -- we're getting these cases done in like a half an hour, and the acceptance on Aurora has been exceptional too. So as I said I think it's the same story for both of those technologies, where you push growth now but into next year will the full impact of these innovations. Geoff Martha: Que, you want to comment on diabetes? Que Dallara: Yeah, look, we continue to push the pipeline in diabetes. Starting with Simplera approved with CE Mark last September, followed by Simplera Sync recently approved that we announced at JPMorgan. And we completed our clinical trials for 780G with Simplera Sync in the US, which we expect to make in this first half of the calendar year. So that's the cadence that you should expect. And as Geoff mentioned in his opening comments, we have next-generation products that we discussed at ADA last year that we continue to make progress on and aggressively moving to get next-generation tethered pumps and patch pumps out to the market. Ryan Weispfenning: Okay. Thank you. Geoff Martha: Thanks, Que. Thanks, Sean. Ryan Weispfenning: Thanks,”